Key Highlights: 92% complete response (CR) rate: Eleven of twelve evaluable patients achieved a centrally confirmed pathologic CR following a single cycle of PRV111; the remaining patient was down-staged from high-grade to low-grade dysplasia. All patients avoided surgery: PRV111 cleared...
Privo Technologies, Inc. a leader in localized cancer therapies, today announced the completion of enrollment in Arm 1 of the Phase 2 run-in portion of its ongoing Phase 2/3 clinical trial (CLN-004) evaluating PRV111, a nano-engineered chemotherapy patch designed to...
Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is thrilled to announce the activation of multiple premier clinical sites across the United States for its ongoing CLN-004 trial. This Phase 2/3, open-label, two-arm study is evaluating the...
Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, is proud to announce the launch of BeneVet Oncology, a new subsidiary dedicated to improving the health and well-being of companion animals....
Privo Technologies is proud to announce the receipt of $4.5 million in funding from the National Cancer Institute to support our pivotal Phase 3 clinical trial for a groundbreaking nanotechnology-based treatment targeting carcinoma in situ of the oral cavity (Stage...
Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG IRB. CLN-004 is a Phase 1/2, open-label, safety and efficacy study accessing the tolerability, anti-tumor effects, systemic exposure, and device...
PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II SBIR Contract from the National Cancer Institute (NCI), part of the National Institutes of Health. The contract will be used...
Privo is excited to share the recent Forbes article titled, "Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems" written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform. ...
PEABODY, Mass., Aug. 24, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo"), a phase 3 clinical stage biopharmaceutical company that has designed and developed a nanoengineered drug delivery platform to safely deliver highly potent drugs locoregionally, announced that Nature Communications published the results...
Peabody, MA – Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Privo's PRV platform delivery of cisplatin for the treatment of carcinoma in situ (CIS) of the anterior...
- © UX Strategy & Digital Branding